指南与共识消化与肝胆胰病理

食管及胃食管交界腺癌新辅助治疗后肿瘤退缩分级:国际德尔菲共识调查结果

Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.
指南 / 共识 · Hum Pathol · 2020-11-19

专家组推荐原发灶采用4级TRG系统,转移淋巴结采用3级系统,并建议作为国际标准。

要点

  • 原发灶推荐4级TRG:1级无残留肿瘤,2级残留<10%,3级残留10%-50%,4级残留>50%。
  • 转移淋巴结推荐3级系统:a级无残留肿瘤,b级部分退缩,c级无退缩。
  • 该TRG系统可推荐为食管及胃食管交界腺癌组织病理学退缩分级的国际标准。

核心结论

  • 专家组推荐原发灶采用4级TRG系统、转移淋巴结采用3级系统,可推荐为食管及胃食管交界腺癌组织病理学TRG分级的国际标准。

研究设计与样本

  • 初始问卷包含43条陈述,涵盖标本处理、大体检查、横切、染色、Barrett食管、TRG系统和淋巴结TRG等主题。
  • 参与者采用5点Likert量表评分,并鼓励对每条陈述撰写评论。

主要发现

  • 专家小组推荐原发灶4级TRG系统:1级无残留肿瘤(完全组织病理学肿瘤退缩),2级残留肿瘤<10%(近完全退缩),3级残留肿瘤10%-50%(部分退缩),4级残留肿瘤>50%(轻微/无退缩)。
  • 推荐转移淋巴结3级系统:a级无残留肿瘤(完全组织病理学TRG),b级部分退缩(肿瘤细胞与退缩并存),c级无退缩(无肿瘤反应迹象)。

关键数值与推荐

  • 原发灶TRG分级:1级无残留肿瘤;2级残留肿瘤<10%;3级残留肿瘤10%-50%;4级残留肿瘤>50%。
  • 转移淋巴结TRG分级:a级无残留肿瘤;b级部分退缩;c级无退缩。

临床怎么用

  • 病理科医生可按推荐的4级原发灶TRG和3级淋巴结TRG系统进行食管及胃食管交界腺癌新辅助治疗后的组织病理学退缩分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complete histopathologic tumor regression after neoadjuvant treatment is a well-known prognostic factor for survival among patients with adenocarcinomas of the esophagus and gastroesophageal junction. The aim of this international Delphi survey was to reach a consensus regarding the most useful tumor regression grading (TRG) system that could represent an international standard for histopathologic TRG grading of gastroesophageal carcinomas. Fifteen pathologists with special interest in esophageal and gastric pathology participated in the online survey. The initial questionnaire contained of 43 statements that addressed the following topics: (1) specimen processing, (2) gross examination, (3) cross sectioning, (4) staining, (5) Barrett's esophagus, (6) TRG systems, and (7) TRG in lymph node (LN). Participants rated the items using a 5-point Likert style scale and were encouraged to write comments for each statement. The expert panel recommended a 4-tiered TRG system for assessing the primary tumor: grade 1: No residual tumor (complete histopathologic tumor regression), grade 2: less than 10% residual tumor (near-complete regression), grade 3: 10%-50% residual tumor (partial regression), grade 4: greater than 50% residual tumor (minimal/no regression), combined with a 3-tiered system for grading therapeutic response in metastatic LNs: grade a: no residual tumor (complete histopathologic TRG), grade b: partial regression (tumor cells and regression), grade c: no regression (no sign of tumor response). This TRG grading system can be recommended as an international standard for histopathologic TRG grading in esophageal and gastroesophageal junction adenocarcinoma.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Saliba G, Detlefsen S, Carneiro F, et al. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey. Hum Pathol. 2020. PMID: 33221343. doi:10.1016/j.humpath.2020.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。